Companion Diagnostics in Non-Small Cell Lung Cancer
Author Information
Author(s): Anastasios Dimou, Kevin Harrington, Kostas N. Syrigos
Primary Institution: Yale University School of Medicine
Hypothesis
Are specific and sensitive molecular tests necessary to define subsets of patients who will benefit from treatment in non-small cell lung cancer?
Conclusion
Companion diagnostics are essential for identifying patients who will benefit from targeted therapies in non-small cell lung cancer.
Supporting Evidence
- Companion diagnostics help determine if specific drugs should be given to cancer patients.
- Testing for EGFR mutations is crucial for the effective use of tyrosine kinase inhibitors.
- ALK fusion protein detection is important for predicting response to crizotinib.
- Histological classification is necessary for appropriate treatment decisions in lung cancer.
Takeaway
Doctors can use special tests to find out which lung cancer patients will get better with certain treatments, helping them choose the best medicine.
Methodology
The paper summarizes recent progress in companion diagnostics and discusses various tests for genetic mutations in lung cancer.
Potential Biases
The lack of a common protocol for testing and potential contamination of samples may introduce bias.
Limitations
Many validation studies for diagnostic tests have been performed in small cohorts and by limited research groups.
Participant Demographics
Patients with adenocarcinoma histology, never smoking status, female gender, and Asian ethnicity are more likely to have EGFR mutations.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website